Sun Pharma Reports Q2 Profit Decline Amid Revenue Growth and Specialty Medicine Expansion
Sun Pharmaceutical reported a 36% year-on-year decline in consolidated net profit to ₹1,988.53 crore for Q2, mainly due to exceptional expenses from a US litigation settlement and its proposed Organon acquisition. Despite this, consolidated revenue rose nearly 12% to ₹16,198.71 crore, driven by growth in India, emerging markets, and specialty medicines like Ilumya. The company’s domestic market share increased to 8.6%. Sun Pharma expects medium-term growth from its innovative portfolio and plans to boost R&D investments in the latter half of FY27.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (62/100). Lens Score 40/100.
Outlets measured: economictimes, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 1 Nov, 12:14 pm. Other outlets followed.